AltruBio Presents New Preclinical Data at FOCIS 2025 Demonstrating ALTB-268’s Efficacy in T Cell-Mediated Inflammatory Models
Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China
Eccogene to Report Preclinical Data with ECC4703, Showcasing Impact on Lean Muscle Sparing and Fat Loss in Combination with Semaglutide and Tirzepatide
TRexBio Doses First Participant in Phase 1 Trial of TRB-061, a Novel TNFR2 Agonist for Atopic Dermatitis and Other Inflammatory Diseases
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate
Sirius Therapeutics announces U.S. FDA Clearance of IND to Begin Clinical Trial of Novel siRNA Therapy for Hyperlipoproteinemia(a)
Ensoma Receives Rare Pediatric Disease and Orphan Drug Designations for EN-374 for Treatment of Chronic Granulomatous Disease
Rejoni completes patient enrollment in pivotal clinical study of a Novel Treatment for the Prevention of Intrauterine Adhesions, the Juveena® Hydrogel System.
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders
Ensoma Unveils Three Programs Leveraging In Vivo Hematopoietic Stem Cell Engineering Platform to Target Genetic, Immune and Oncological Diseases
